Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02028442
Other study ID # ColoAd1-1001
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date September 20, 2012
Est. completion date April 29, 2016

Study information

Verified date March 2020
Source PsiOxus Therapeutics Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicentre, open-label, Phase I/II study of enadenotucirev in patients with either solid tumour of epithelial origin not responding to standard therapy or for whom no standard treatment exists (Phase I dose escalation stage Single cycle), mCRC not responding to standard therapy (Phase I dose escalation Repeat cycle cohort expansion stage ), mCRC not responding to standard therapy or advanced or metastatic bladder cancer not candidate for chemotherapy (Phase Ib) or mCRC in stable disease or partial response after 3-4 months of first line standard of care chemotherapy (Phase II).


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date April 29, 2016
Est. primary completion date April 29, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients must provide written informed consent

- Age = 18 years and the patient must be at least the legal age limit to be able to give consent within the jurisdiction the study is taking place.

- ECOG performance status 0 or 1

- Predicted life expectancy of 3 months or more

- Ability to comply with study procedures in the Investigator's opinion

- Recovered to Grade 1 from the effects (excluding alopecia) of any prior therapy for their malignancies

- Adequate renal function

- Creatinine = 1.5 mg/dL or calculated creatinine clearance using the Cockcroft-Gault formula = 60 mL/min, or measured creatinine clearance = 60 mL/min, Haematuria: dipstick = 2+

- Proteinuria: dipstick = 2+

- Adequate hepatic function

- Serum bilirubin < 1.5 mg/dL

- Aspartate transaminase (AST) and alanine transaminase (ALT) = 3x upper limit of normal (ULN)

- Adequate bone marrow function:

- Absolute neutrophil count (ANC) = 1.5 x 109/L

- Platelets = 100 x 109/L

- Haemoglobin = 100 g/L for UCC and = 90 g/L for other cancers

- Adequate coagulation tests: international normalised ratio (INR) = 1.5 x ULN

- For females of childbearing potential (defined as <2 years after last menstruation or not surgically sterile), a negative serum pregnancy test must be documented within 14 days prior to first administration of study treatment

- For women who are not postmenopausal (24 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception, during the treatment period and for at least 3 months after the last dose of study drug

- For men: agreement to use a barrier method of contraception during the treatment period and for at least 6 months after the last dose of study drug

- At least 3 weeks since any dose of IV systemic chemotherapy and at least two weeks since any oral dose of capecitabine at the time of first administration of ColoAd1.

Phase I Specific Inclusion Criteria:

Dose Escalation Stage only (except Repeat Cycle Cohort):

- Solid tumour of epithelial origin not responding to standard therapy or for whom no standard treatment exists

Dose Expansion Stage Single Cycle and Dose Escalation Stage Repeat Cycle Cohort:

- mCRC not responding to standard therapy

- = 3 prior lines of systemic therapy for advanced disease OR = 4 prior lines of systemic therapy for advanced disease if one of the 4 lines was an anti EGFR therapy given as a single agent or combined to a previously administered chemotherapy regimen Phase Ib:mCRC not responding to standard therapy

- no more than 3 prior lines of systemic therapy for advanced disease OR no more than 4 prior lines of systemic therapy for advanced disease if one of the 4 lines was an anti EGFR therapy given as a single agent or combined to a previously administered chemotherapy regimen

- Advanced or metastatic UCC, who have received a maximum of one chemotherapy-containing regimen and a maximum of one other systemic treatment with biologic agents only.

Phase II Specific Inclusion Criteria:

- mCRC

- Have received 3 - 4 months of first line chemotherapy with either FOLFOX, FOLFIRI or CAPOX, with or without bevacizumab

- At least one measurable lesion according to RECIST 1.1 criteria

- Documented partial response or stable disease

- Eligible to receive chemotherapy with FOLFOX or CAPOX after a short chemotherapy interruption (3 to 4 weeks)

Exclusion Criteria for all Patients:

- Pregnant or breast feeding females;

- Known history or evidence of significant immunodeficiency due to underlying illness (e.g. human immunodeficiency virus [HIV]/acquired immunodeficiency syndrome [AIDS]) and/or medication (e.g. systemic corticosteroids, or other immunosuppressive medications including cyclosporine, azathioprine, interferons, within the past 4 weeks)

- Splenectomy

- Prior allogeneic or autologous bone marrow or organ transplantation

- Active infections requiring antibiotics, physician monitoring, or recurrent fevers >38.0 degrees centigrade associated with a clinical diagnosis of active infection

- Active viral disease or known positive serology for HIV, hepatitis B or hepatitis C;

- Use of the following anti-viral agents: ribavirin, adefovir, lamivudine or cidofovir within 7 days prior to day 1; or pegylated interferon (PEG-IFN) (within 14 days prior to first administration of ColoAd1)

- Administration of an investigational drug within 28 days prior to first dose of ColoAd1

- Major surgery within 4 weeks or radiotherapy within 3 weeks prior to first dose of ColoAd1

- Another primary malignancy within the past 3 years (except for non melanoma skin cancer or cervical cancer in situ)

- Central nervous system (CNS) metastasis that is symptomatic and/or requires treatment

- Any condition or illness that, in the opinion of the Investigator or the medical monitor, would compromise patient safety or interfere with the evaluation of the safety of the drug

- Known allergy to treatment medication or its excipients

- Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent

Phase II Specific Exclusion Criteria:

- Progression on first line therapy

- A complete response on first line therapy

- Use of first line therapy for longer than 4 months

- Use of any first line treatment with a chemotherapy regimen other than FOLFOX, FOLFIRI or CAPOX (each with or without bevacizumab)

- More than 6 weeks since the last administration of 5 FU, capecitabine, oxaliplatin or irinotecan

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Enadenotucirev
Oncolytic virus

Locations

Country Name City State
Belgium Cliniques Universitaires St Luc Bruxelles
Belgium Ghent University Hospital Ghent
Belgium GZA ziekenhuizen campus Sint-Augustinus Wilrijk Antwerp
Spain Institut Catala d Oncologica Barcelona
Spain START - Hospital Universitario Madrid Sanchinarrio Madrid
Spain Hospital Universitario Virgen del Rocio (HUVR) Seville

Sponsors (1)

Lead Sponsor Collaborator
PsiOxus Therapeutics Ltd

Countries where clinical trial is conducted

Belgium,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase 1 - Maximum Tolerated Dose - Maximum tolerated dose (MTD) / maximum feasible dose (MFD) of enadenotucirev when administered by sub-acute fractionated IV injection (phase I Dose Escalation) and recommended dose for phase II. Up to Day 22
Primary Phase 1b - Selection of suitable schedule for repeat cycle IV administration Open label assessment of 2 repeat cycle schedules, with expansion cohort at the MTD or MFD with best repeat cycle schedule in advanced/metastatic UBC patients. Up to Day 134
See also
  Status Clinical Trial Phase
Completed NCT01228734 - A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients Phase 3
Completed NCT05178745 - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Completed NCT01591421 - P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. Phase 1/Phase 2
Withdrawn NCT05412706 - Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy Phase 2
Withdrawn NCT04430985 - FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer Phase 2
Withdrawn NCT03182894 - Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05725200 - Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Phase 2
Terminated NCT03176264 - PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer Phase 1
Completed NCT04866290 - HepaSphereâ„¢ Microspheres Prospective Registry
Not yet recruiting NCT06425133 - Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers Phase 2
Not yet recruiting NCT05531045 - 18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
Withdrawn NCT03982173 - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors Phase 2
Completed NCT02906059 - Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer Phase 1
Active, not recruiting NCT02575378 - Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer Phase 4
Withdrawn NCT02535988 - Abscopal Effect for Metastatic Colorectal Cancer Phase 2
Recruiting NCT02848807 - Chemotherapy-related Toxicity, Nutritional Status and Quality of Life N/A
Active, not recruiting NCT02077868 - Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Phase 3
Completed NCT02414009 - Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients Phase 2
Active, not recruiting NCT01949194 - Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers Phase 2
Withdrawn NCT01915472 - A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer Phase 2